Business
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)
Presentations highlight patient preference for sebetralstat, early treatment as the strongest driver of response, and sustained effectiveness with use in
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"text","content":"\nPresentations highlight patient preference for sebetralstat, early treatment as the strongest driver of response, and sustained effectiveness with use in clinical trials\n\n\n FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--\nKalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data from its sebetralstat clinical trial program presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting and the Western Society of Allergy, Asthma & Immunology (WSAAI) 63rd Annual Scientific Session. The presentations demonstrate a significant shift in how patients manage hereditary angioedema (HAE) attacks when provided with access to sebetralstat, a safe and effective oral on-demand treatment. By reducing barriers to treatment, sebetralstat enabled early intervention which was associated with an improved treatment response. Collectively, the results highlight the potential of oral sebetralstat to help patients treat more attacks, earlier, with sustained efficacy and high satisfaction.\n\n\n“The data presented at AAAAI and WSAAI reinforce the importance of treating HAE attacks early, which is consistently associated with improved outcomes,” said Ben Palleiko, CEO of KalVista. “In the KONFIDENT-S open-label extension, we are observing sustained effectiveness and high patient satisfaction with repeated use of sebetralstat, along with meaningful changes in treatment behavior, including treating the majority of attacks, early intervention, and preference for an oral option. Together, these findings support our belief that EKTERLY has the potential to transform how HAE is managed and deliver sustained real-world benefit for people living with HAE.”\n\n\nPatterns Associated with Repeated Treatment with Sebetralstat for Multiple HAE Attacks in the KONFIDENT-S Open-Label Study was presented at WSAAI by Marc Riedl, MD, Professor of Medicine and Clinical Director, US Hereditary Angioedema Association Center at the University of California, San Diego, and an investigator for the KONFIDENT phase 3 trial.\n\n\n\nAs of July 9, 2025, 2,464 HAE attacks were treated with sebetralstat. Across the first 30 attacks for participants:\n\n\nThe use of a second dose occurred in 19.3% of attacks and showed a decreasing trend from the first through the 30th attack.\n\n\n\nThe use of conventional injectable treatments...